Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.5
2.7
Journals
Applied Sciences
Special Issues
Biopharmaceutics and Multivariate Modeling of Complex Systems
share announcement

Biopharmaceutics and Multivariate Modeling of Complex Systems

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Biomedical Engineering".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 2411

Special Issue Editors

Prof. Dr. Aleksander Mendyk

E-Mail Website
Guest Editor
Chair of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University-Medical College,30-688 Kraków, Poland
Interests: machine learning; artificial intelligence; pharmaceutical technology; biopharmaceutics; clinical trials; statistics
Special Issues, Collections and Topics in MDPI journals
Dr. Jakub Szlęk

E-Mail Website
Guest Editor
Chair and Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University-Medical College, Medyczna 9 St, 30-688 Kraków, Poland
Interests: pharmaceutical technology; machine learning; solid dosage forms; drug dissolution; biopharmaceutics
Special Issues, Collections and Topics in MDPI journals
Dr. Adam Pacławski

E-Mail Website
Guest Editor
Chair and Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University-Medical College, Medyczna 9 St, 30-688 Kraków, Poland
Interests: artificial intelligence; machine learning; pulmonary drug delivery; particle technology; spray drying; biopharmaceutics; image processing and analysis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Fellow Researchers,

The growth of biopharmaceutics from the traditional “science of administrations routes” towards systems biology and sophisticated computational techniques has been remarkable. The abovementioned tools are devoted to handling complexity of the analyzed problems. Biopharmaceutics currently plays a pivotal role in both drug development and drug discovery. For the latter, biopharmaceutics provides a holistic way to address the druggability of new drug candidates.

This Special Issue is dedicated to the modeling approaches employed in the field of biopharmaceutics, where multivariate and multidimensional relationships are captured, explained and eventually put into use for efficient drug discovery and development processes. We welcome all flavors of in silico endeavors directed towards the quantitative description of each and every element of the famous LADME/Tox. This includes both mechanistic and empirical approaches, for the latter with special emphasis on artificial intelligence tools.

As our ambition is to present the current state-of-the-art of the field, we welcome both experimental and review papers. We would like to encourage software programmers and developers to publish their software packages as open source and provide case studies with this software employed in the biopharmaceutics area.

We look forward to your exciting contributions.

Prof. Dr. Aleksander Mendyk
Dr. Jakub Szlęk
Dr. Adam Pacławski
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biopharmaceutics
  • quantitative systems pharmacology
  • pharmacometrics
  • physiology-based pharmacokinetic modeling and simulation
  • artificial intelligence
  • chemometrics

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1492 KiB  
Article
Computational-Model-Based Biopharmaceutics for p53 Pathway Using Modern Control Techniques for Cancer Treatment
by Amina Yasin, Abdul Rehman Yasin, Muhammad Rizwan Azam, Ali Raza, Robina Nazir and Ridab Adlan Elamin Abdalla
Appl. Sci. 2022, 12(11), 5748; https://doi.org/10.3390/app12115748 - 06 Jun 2022
Cited by 1 | Viewed by 1707
Abstract
The p53 pathway has been the focus of many researchers in the last few decades owing to its pivotal role as a frontline cancer suppressant protein. It plays a vital role in maintaining cell cycle checkpoints and cell apoptosis in response to a [...] Read more.
The p53 pathway has been the focus of many researchers in the last few decades owing to its pivotal role as a frontline cancer suppressant protein. It plays a vital role in maintaining cell cycle checkpoints and cell apoptosis in response to a broken DNA strand. This is why it is found in the mutated form in more than 50% of malignant tumors. To overcome this, various drugs have been proposed to revive the p53 pathway in cancer patients. Small-molecule-based drugs, such as Nutlin 3a, which are capable of performing this stimulation, are at the fore of advanced clinical trials. However, the calculation of their dosage is a challenge. In this work, a method to determine the dosage of Nutlin 3a is investigated. A control-systems-based model is developed to study the response of the wild-type p53 protein to this drug. The proposed strategy regulates the p53 protein along with negative and positive feedback loops mediated by the MDM2 and MDM2 mRNA, respectively, along with the reversible repression of MDM2 caused by Nutlin 3a. For a broader perspective, the reported PBK dynamics of Nutlin 3a are also incorporated. It has been reported that p53 responds to stresses in two ways in terms of concentration to this drug: either it is a sustained (constant) or an oscillatory response. The claimed dosage strategy turned out to be appropriate for sustained p53 response. However, for the induction of oscillations, inhibition of MDM2 is not enough; rather, anti-repression of the p53–MDM2 complex is also needed, which opens new horizons for a new drug design paradigm. Full article
(This article belongs to the Special Issue Biopharmaceutics and Multivariate Modeling of Complex Systems)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop